Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Deferred Tax Liability (2018 - 2020)

Akebia Therapeutics (AKBA) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $35.1 million as the latest value for Q1 2020.

  • Quarterly Non-Current Deferred Tax Liability rose 806.04% to $35.1 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $35.1 million through Mar 2020, up 806.04% year-over-year, with the annual reading at $119.4 million for FY2018, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability for Q1 2020 was $35.1 million at Akebia Therapeutics, up from $1.8 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $119.4 million in Q4 2018, with the low at $1.8 million in Q3 2019.
  • Average Non-Current Deferred Tax Liability over 3 years is $32.6 million, with a median of $3.9 million recorded in 2019.
  • Peak annual rise in Non-Current Deferred Tax Liability hit 806.04% in 2020, while the deepest fall reached 806.04% in 2020.
  • Over 3 years, Non-Current Deferred Tax Liability stood at $119.4 million in 2018, then tumbled by 98.53% to $1.8 million in 2019, then surged by 1903.42% to $35.1 million in 2020.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $35.1 million, $1.8 million, and $3.0 million for Q1 2020, Q3 2019, and Q2 2019 respectively.